Bioimpedance Analysis Guided Volume Expansion for the Prevention of Contrast Induced-acute Kidney Injury

Bioimpedance Analysis Guided Volume Expansion for the Prevention of Contrast

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02449317

Acronym

BELIEVE

Enrollment

Registered

2015-05-20

Start date

2015-05-31

Completion date

2016-01-31

Last updated

2017-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

X-ray Contrast Media Adverse Reaction

Keywords

contrast induced acute kidney injury, bioimpedance

Brief summary

Bioelectrical impedance analysis guided volume expansion for the prevention of contrast induced-acute kidney injury

Detailed description

Compared bioelectrical impedance analysis guided hydration therapy versus standard hydration for the prevention of contrast induced-acute kidney injury

Interventions

OTHERBioimpedance guided

bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water * extracellular water/total body water \< 0.36 : 4 ml/kg/hr * extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr * extracellular water/total body water \> 0.4 : 1 ml/kg/hr

OTHERstandard hydration

standard hydration : 7.5%Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

1. Age 18-90 yr 2. Chronic kidney disease stage 3 & 4 (eGFR 15-60 ml/min/m2) 3. elective cardiac catheterization

Exclusion criteria

1. Contrast media administration in the past 14 days 2. congestive heart failure (NYHA III-IV, ascites , pleuropericardial effusion ,severe valvular heart disease 3. Kidney transplant status or RRT 4. Emergency cardiac catheterization 5. Allergy to radiographic contrast media 6. Unstable renal function (change in serum creatinine ≥ 0.5 mg/dl or 25% within 14 days prior to the study 7. Not inform consent 8. left ventricular ejection fraction \< 40 % 9. Liver cirrhosis child B or C 10. Dosage of angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker changed in past 2 wk

Design outcomes

Primary

Measure	Time frame	Description
serum creatinine at 48-72 hours after contrast administration	48-72 hr	Acute kidney injury

Secondary

Measure	Time frame	Description
serum creatinine at 2 weeks after contrast administration	2 weeks	Renal replacement therapy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026